Literature DB >> 20141134

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Sujata S Shinde1, Andrej Maroz, Michael P Hay, Adam V Patterson, William A Denny, Robert F Anderson.   

Abstract

The mechanism by which the 1,2,4-benzotriazine 1,4-dioxide (BTO) class of bioreductive hypoxia-selective prodrugs (HSPs) form reactive radicals that kill cancer cells has been investigated by steady-state radiolysis, pulse radiolysis (PR), electron paramagnetic resonance (EPR), and density functional theory (DFT) calculations. Tirapazamine (TPZ, 3-amino BTO, 1) and a series of 3-substituted analogues, -H (2), -methyl (3), -ethyl (4), -methoxy (5), -ethoxymethoxy (6), and -phenyl (7), were reduced in aqueous solution under anaerobic steady-state radiolysis conditions, and their radicals were found to remove the substrates by short chain reactions of different lengths in the presence of formate ions. Multiple carbon-centered radical intermediates, produced upon anaerobic incubation of the compounds with cytochrome P(450) reductase enriched microsomes, were trapped by N-tert-butyl-alpha-phenylnitrone and observed using EPR. The highly oxidizing oxymethyl radical, from compound 5, was identified, and experimental spectra obtained for compounds 1, 2, 3, and 7 were well simulated after the inclusion of aryl radicals. The identification of a range of oxidizing radicals in the metabolism of the BTO compounds gives a new insight into the mechanism by which these HSPs can cause a wide variety of damage to biological targets such as DNA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20141134     DOI: 10.1021/ja908689f

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  13 in total

1.  Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Authors:  Kevin O Hicks; Bronwyn G Siim; Jagdish K Jaiswal; Frederik B Pruijn; Annie M Fraser; Rita Patel; Alison Hogg; H D Sarath Liyanage; Mary Jo Dorie; J Martin Brown; William A Denny; Michael P Hay; William R Wilson
Journal:  Clin Cancer Res       Date:  2010-08-20       Impact factor: 12.531

2.  Isotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-N-oxide.

Authors:  Xiulong Shen; Anuruddha Rajapakse; Fabio Gallazzi; Venkatraman Junnotula; Tarra Fuchs-Knotts; Rainer Glaser; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2013-12-19       Impact factor: 3.739

3.  Systematic and Molecular Basis of the Antibacterial Action of Quinoxaline 1,4-Di-N-Oxides against Escherichia coli.

Authors:  Guyue Cheng; Bei Li; Chenxi Wang; Hongfei Zhang; Guixia Liang; Zhifei Weng; Haihong Hao; Xu Wang; Zhenli Liu; Menghong Dai; Yulian Wang; Zonghui Yuan
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 4.  Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Authors:  Annika Foehrenbacher; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-12-27       Impact factor: 6.244

5.  Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Authors:  Kevin M Johnson; Zachary D Parsons; Charles L Barnes; Kent S Gates
Journal:  J Org Chem       Date:  2014-07-25       Impact factor: 4.354

6.  Mechanisms of Antibacterial Action of Quinoxaline 1,4-di-N-oxides against Clostridium perfringens and Brachyspira hyodysenteriae.

Authors:  Fanfan Xu; Guyue Cheng; Haihong Hao; Yulian Wang; Xu Wang; Dongmei Chen; Dapeng Peng; Zhenli Liu; Zonghui Yuan; Menghong Dai
Journal:  Front Microbiol       Date:  2016-12-05       Impact factor: 5.640

7.  Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity.

Authors:  Aušra Nemeikaitė-Čėnienė; Jonas Šarlauskas; Violeta Jonušienė; Audronė Marozienė; Lina Misevičienė; Aliaksei V Yantsevich; Narimantas Čėnas
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

Review 8.  Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.

Authors:  Christopher P Guise; Alexandra M Mowday; Amir Ashoorzadeh; Ran Yuan; Wan-Hua Lin; Dong-Hai Wu; Jeff B Smaill; Adam V Patterson; Ke Ding
Journal:  Chin J Cancer       Date:  2013-07-12

Review 9.  ABC transporters in CSCs membranes as a novel target for treating tumor relapse.

Authors:  Laura Zinzi; Marialessandra Contino; Mariangela Cantore; Elena Capparelli; Marcello Leopoldo; Nicola A Colabufo
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

Review 10.  Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.

Authors:  Guyue Cheng; Wei Sa; Chen Cao; Liangliang Guo; Haihong Hao; Zhenli Liu; Xu Wang; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-03-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.